+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome

Dexamethasone implant as an effective treatment option for macular edema due to Irvine-Gass syndrome

Journal of Cataract and Refractive Surgery 41(9): 1954-1961

To investigate the effectiveness and safety of a dexamethasone implant (Ozurdex) to treat pseudophakic macular edema (Irvine-Gass syndrome). Department of Ophthalmology, Ludwig-Maximilians-University Munich, Munich, Germany. Prospective nonrandomized study. Preoperatively and in 12 monthly postoperative intervals, a complete ophthalmic examination was performed in study patients, including measurement of corrected distance visual acuity (CDVA) using the standard Early Treatment Diabetic Retinopathy Study chart, intraocular pressure, foveal thickness using spectral-domain optical coherence tomography (SD-OCT), and retinal sensitivity (mean defect depth) using microperimetry. Morphological aspects of the inner segment-outer segment junction and visual function were correlated. Twenty-three eyes (23 patients) with pseudophakic macular edema after uneventful cataract surgery were included. The mean duration of macular edema before treatment with a dexamethasone implant was 5.4 months (range 2 to 8 months). The CDVA increased in all patients from 30.2 letters ± 4.3 (SD) at baseline to 50.4 ± 4.9 letters at 12 months (P = .0016), regardless of the time of macular edema duration. Foveal thickness decreased from 520.8 ± 71.4 μm to 232.7 ± 26.6 μm (P < .002). Retinal sensitivity (mean defect depth) increased significantly over a 12-month follow-up, correlating positively with a restored inner segment-outer segment junction on SD-OCT analyses. No relevant adverse events were reported, and 9 recurrences occurred with a peak after 3 months and required a second dexamethasone implant injection. The dexamethasone implant was safe and effective in treating pseudophakic macular edema regardless of the duration of the edema. Drs. Mayer and Haritoglou are consultants to Allergan, Inc. No author has a financial or proprietary interest in any material or method mentioned.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057606824

Download citation: RISBibTeXText

PMID: 26603404

DOI: 10.1016/j.jcrs.2015.10.025

Related references

Dexamethasone implant as an effective treatment option for macular edema in Irvine-Gass syndrome. Journal of Cataract and Refractive Surgery 42(4): 648, 2016

Treatment of postoperative cystoid macular edema (Irvine-Gass syndrome) with dexamethasone 0.7 mg intravitreal implant. Journal Francais d'Ophtalmologie 39(1): 5, 2016

Dexamethasone intravitreal implant for treatment of patients with recalcitrant macular edema resulting from Irvine-Gass syndrome. Investigative Ophthalmology and Visual Science 54(5): 3320-3324, 2013

Intravitreal injection of dexamethasone implant and ranibizumab in cystoid macular edema in the course of irvine-gass syndrome. Case Reports in Ophthalmology 5(2): 243-248, 2014

Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. American Journal of Ophthalmology 147(6): 1048-54 1054.E1-2, 2009

Treatment of persistent macular edema associated with uveitis or irvine gass syndrome with an intravitreal bioerodible sustained dexmethasone release implant a prospective controlled multi center clinical trial. ARVO Annual Meeting Abstract Search & Program Planner : Abstract No 4309, 2003

Treatment of cystoid macular edema with bevacizumab in course of Irvine-Gass syndrome. Klinika Oczna 115(1): 61-64, 2013

Intravitreal ranibizumab for the treatment of cystoid macular edema in Irvine-Gass syndrome. Journal of Ocular Pharmacology and Therapeutics 28(6): 636-639, 2012

Chronic macular edema medical treatment in Irvine-Gass syndrome: case report. European Journal of Ophthalmology 20(2): 462-465, 2010

Evaluation of best corrected visual acuity and central macular thickness after intravitreal dexamethasone implant injections in patients with Irvine-Gass syndrome: A retrospective study of six cases. Therapie 71(5): 457-465, 2016

Comparison of topical nepafenac 0.1% with intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome. International Journal of Ophthalmology 12(2): 258-267, 2019

Central serous chorioretinopathy in the fellow eye as a complication of intravitreal dexamethasone implant for the treatment of Irvine-Gass syndrome. Clinical and Experimental Optometry 99(6): 601-603, 2016

Macular edema in Irvine-Gass syndrome. Klinika Oczna 45(10-11): 1149-1153, 1975

Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops. Ophthalmic Surgery Lasers and Imaging Retina 48(11): 936-942, 2017

Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocular Immunology and Inflammation 19(3): 216-218, 2011